Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment

被引:3
|
作者
Wang, Chuanlin [1 ,2 ]
Gao, Pengning [1 ,2 ]
Xu, Jiali [1 ,2 ]
Liu, Shanling [1 ,2 ]
Tian, Wenda [2 ,3 ]
Liu, Jiayu [4 ]
Zhou, Lan [1 ,2 ]
机构
[1] Kunming Med Univ, Yunnan Canc Hosp, Dept Clin Nutr, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China
[2] Yunnan Canc Ctr, Kunming, Yunnan, Peoples R China
[3] Kunming Med Univ, Yunnan Canc Hosp, Dept Gynecol, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China
[4] Anhui Med Univ, Key Lab Environm Toxicol Anhui Higher Educ Inst, Sch Publ Hlth, Dept Toxicol, Hefei, Anhui, Peoples R China
关键词
phytochemicals; ovarian cancer; PARP; BRCA; PARP inhibitors; ANTIOXIDANT DEFENSE SYSTEM; ENDOTHELIAL DYSFUNCTION; DNA-REPAIR; DAMAGE; KEAP1; CROCIN; TUMORS; CELLS; NRF2; ROS;
D O I
10.3389/fphar.2022.1078303
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ovarian cancer is among the most common malignant tumors in gynecology and is characterized by insidious onset, poor differentiation, high malignancy, and a high recurrence rate. Numerous studies have shown that poly ADP-ribose polymerase (PARP) inhibitors can improve progression-free survival (PFS) in patients with BRCA-mutated ovarian cancer. With the widespread use of BRCA mutation and PARP inhibitor (PARPi) combination therapy, the side effects associated with BRCA mutation and PARPi have garnered attention worldwide. Mutations in the BRCA gene increase KEAP1-NRF2 ubiquitination and reduce Nrf2 content and cellular antioxidant capacity, which subsequently produces side effects such as cardiovascular endothelial damage and atherosclerosis. PARPi has hematologic toxicity, producing thrombocytopenia, fatigue, nausea, and vomiting. These side effects not only reduce patients' quality of life, but also affect their survival. Studies have shown that natural phytochemicals, a class of compounds with antitumor potential, can effectively prevent and treat the side effects of chemotherapy. Herein, we reviewed the role of natural phytochemicals in disease prevention and treatment in recent years, including sulforaphane, lycopene, catechin, and curcumin, and found that these phytochemicals have significant alleviating effects on atherosclerosis, nausea, and vomiting. Moreover, these mechanisms of action significantly correlated with the side-effect-producing mechanisms of BRCA mutations and PARPi. In conclusion, natural phytochemicals may be effective in alleviating the side effects of BRCA mutant ovarian cancer cells and PARP inhibitors.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
    Mittra, Arjun
    Coyne, Geraldine H. O' Sullivan
    Zlott, Jennifer
    Kummar, Shivaani
    Meehan, Robert
    Rubinstein, Lawrence
    Juwara, Lamin
    Wilsker, Deborah
    Ji, Jiuping
    Miller, Brandon
    Navas, Tony
    Ferry-Galow, Katherine V.
    Voth, Andrea Regier
    Chang, Ting-Chia
    Jiwani, Shahanawaz
    Parchment, Ralph E.
    Doroshow, James H.
    Chen, Alice P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (03) : 177 - 189
  • [32] BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms
    Marciano, Naomie Devico
    Kroening, Gianna
    Dayyani, Farshid
    Zell, Jason A.
    Lee, Fa-Chyi
    Cho, May
    Valerin, Jennifer Goldstein
    CANCERS, 2022, 14 (10)
  • [33] Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
    Colombo, ILaria
    Lheureux, Stephanie
    Oza, Amit Manulal
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 605 - 617
  • [34] RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
    Cruz, C.
    Castroviejo-Bermejo, M.
    Gutierrez-Enriquez, S.
    Llop-Guevara, A.
    Ibrahim, Y. H.
    Gris-Oliver, A.
    Bonache, S.
    Morancho, B.
    Bruna, A.
    Rueda, O. M.
    Lai, Z.
    Polanska, U. M.
    Jones, G. N.
    Kristel, P.
    de Bustos, L.
    Guzman, M.
    Rodriguez, O.
    Grueso, J.
    Montalban, G.
    Caratu, G.
    Mancuso, F.
    Fasani, R.
    Jimenez, J.
    Howat, W. J.
    Dougherty, B.
    Vivancos, A.
    Nuciforo, P.
    Serres-Creixams, X.
    Rubio, I. T.
    Oaknin, A.
    Cadogan, E.
    Barrett, J. C.
    Caldas, C.
    Baselga, J.
    Saura, C.
    Cortes, J.
    Arribas, J.
    Jonkers, J.
    Diez, O.
    O'Connor, M. J.
    Balmana, J.
    Serra, V
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1203 - 1210
  • [35] Methylated circulating tumor DNA as a potential marker of PARP inhibitor efficiency in BRCA mutated ovarian cancer patients
    Steffensen, Karina Dahl
    Andersen, Rikke Fredslund
    Jakobsen, Anders Kristian Moeller
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
    Yang, Shicheng
    Green, Allen
    Brown, Needa
    Robinson, Alexis
    Senat, Merline
    Testino, Bryanna
    Dinulescu, Daniela M.
    Sridhar, Srinivas
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [37] Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation
    Zhang, Ruijie
    Wang, Tiffany
    Lin, Jiayuh
    ANTICANCER RESEARCH, 2021, 41 (05) : 2277 - 2286
  • [38] Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer
    Hobbs, Evthokia A.
    Litton, Jennifer K.
    Yap, Timothy A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (14) : 1825 - 1837
  • [39] Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer
    Le, Dan
    Gelmon, Karen A.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (09) : 833 - 839
  • [40] MAINTENANCE TREATMENT WITH OLAPARIB IN BRCA-MUTATED HIGH GRADE SEROUS OVARIAN CANCER (HGSOC): OUR EXPERIENCE IN A CASE REPORT
    Mainella, A.
    Giacomi, N.
    Marmissolle, F.
    Vigo, S.
    Price, P.
    Sansano, M.
    Lujan, M. L.
    Zapata Caamano, G.
    Dominguez, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1585 - 1585